Saturday 17 October 2026
Export FLNA’s income statement to Excel — free account
Cassava Sciences, Inc.
FLNA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 80.4% and free cash flow grew 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.71
0.05
−6.58%
Follow FLNA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.23 | 11.62 | 9.13 | 29.91 | 19.51 | 50.40 | 16.83 | 39.22 | 9.42 | 28.68 |
Net Debt/EBITDA |
1.01 | 0.92 | 1.16 | 2.55 | 7.22 | 14.56 | 4.71 | 3.00 | 0.88 | 1.26 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.35 | 4.80 | 0.84 | 1.02 | 0.93 | 0.85 | 0.54 | 0.73 | 0.69 | 0.82 |
Capex/Depreciation |
(0.62) | (0.09) | (0.27) | (2.08) | (41.60) | 16.36 | (0.31) | 0.00 | 0.00 | (1.29) |
| (82.66%) | (17.19%) | (53.27%) | (31.67%) | (18.71%) | (11.08%) | (22.20%) | (44.72%) | (84.07%) | (61.87%) | |
| (65.95%) | (15.75%) | (50.31%) | (30.40%) | (17.94%) | (10.76%) | (21.23%) | (42.34%) | (79.06%) | (57.99%) | |
ROIC |
0.00% | (516.08%) | (405.48%) | (188.56%) | (100.31%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(122.08%) | (16.70%) | (70.81%) | (33.58%) | (12.82%) | (6.87%) | (21.04%) | (33.43%) | (122.96%) | (79.68%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.68) | (2.53) | (1.97) | (2.00) | (1.33) | (0.19) | (0.15) | (0.45) | (1.26) | (1.89) |
Cash per Share |
1.98 | 2.78 | 2.89 | 5.00 | 5.92 | 3.58 | 1.33 | 1.85 | 1.60 | 2.87 |
Shareholders Equity per Share |
1.54 | 3.15 | 3.28 | 5.66 | 6.44 | 3.53 | 1.27 | 1.84 | 1.48 | 2.86 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.54 | 3.15 | 3.28 | 5.66 | 6.44 | 3.53 | 1.27 | 1.84 | 1.48 | 2.86 |
Free Cash Flow |
(32.83) | (117.03) | (82.44) | (80.23) | (52.41) | (5.02) | (2.53) | (4.77) | (8.24) | (12.31) |
Working Capital |
53.88 | 124.78 | 115.44 | 204.16 | 231.95 | 92.13 | 21.96 | 19.53 | 9.53 | 18.41 |
Capital Expenditures |
(0.58) | (0.10) | (0.41) | (2.71) | (22.21) | 0.36 | (0.02) | — | — | (0.07) |
Net Current Asset Value |
53.76 | 124.70 | 115.44 | 203.93 | 231.62 | 91.89 | 21.96 | 19.53 | 9.53 | 18.41 |
| Other line items | ||||||||||
Quick Ratio |
2.18 | 10.94 | 8.53 | 28.46 | 18.62 | 50.14 | 16.64 | 38.76 | 9.26 | 28.14 |
Depreciation/Fixed assets |
0.05 | 0.05 | 0.07 | 0.06 | 0.03 | 2.00 | 1.23 | 0.79 | 0.44 | 0.25 |
Cash ROIC |
(19.32%) | (42.67%) | (31.88%) | (18.72%) | (10.75%) | (2.70%) | (5.60%) | (12.10%) | (40.82%) | (32.95%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.67) | (2.52) | (1.96) | (1.93) | (0.77) | (0.21) | (0.14) | (0.45) | (1.26) | (1.88) |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.07) | (0.56) | 0.01 | 0.00 | 0.00 | 0.00 | (0.01) |
Average Payables |
24.65 | 9.11 | 7.30 | 5.57 | 4.02 | 0.68 | 0.37 | 0.36 | 0.36 | 0.67 |
Average Assets |
137.94 | 154.60 | 193.25 | 250.81 | 180.54 | 58.89 | 21.81 | 15.49 | 15.07 | 25.61 |
Average Common Equity |
110.05 | 141.59 | 182.50 | 240.73 | 173.06 | 57.15 | 20.86 | 14.66 | 14.17 | 24.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Columns are period end dates